Piramal Pharma Ltd (PPLPHARMA) — Corporate Action | 29 September 2026
Piramal Pharma disclosed a GST audit order requiring Rs. 4,06,03,220 in input tax credit demand and penalty for FY 2020-21 to 2022-23, which it plans to appeal without expecting material financial impact.
About Piramal Pharma Ltd (PPLPHARMA)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when PPLPHARMA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track PPLPHARMA — Free💡 Ask AI about this filing
📊 More PPLPHARMA filings
- 🔴 Announcement — 18 September 2026Piramal Pharma disclosed that an independent ESG rating agency, Niche99, assigned it an ESG score of...
- 🔴 Announcement — 14 September 2026Piramal Pharma disclosed that the US FDA conducted a GMP inspection at its Morpeth, UK facility from...
- 🔴 Announcement — 8 September 2026Piramal Pharma announced its schedule for upcoming institutional investor meetings in late September...
- 🔴 Announcement — 3 September 2026Piramal Pharma disclosed that NSE Sustainability Ratings and Analytics assigned an ESG rating of 65 ...
- 🔴 Announcement — 18 August 2026Piramal Pharma announced it completed the acquisition of an additional 40.67% stake in Yapan Bio Pri...
🔥 Also filed on 29 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when PPLPHARMA files new disclosures
Track PPLPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track PPLPHARMA — FreeFree account · 2 AI queries/day